Percheron Therapeutics Future Growth
Future criteria checks 0/6
Percheron Therapeutics's revenue and earnings are forecast to decline at 0.9% and 15.9% per annum respectively. EPS is expected to decline by 18% per annum. Return on equity is forecast to be -231% in 3 years.
Key information
-15.9%
Earnings growth rate
-18.0%
EPS growth rate
Pharmaceuticals earnings growth | 56.3% |
Revenue growth rate | -0.9% |
Future return on equity | -231.0% |
Analyst coverage | Low |
Last updated | 10 Sep 2024 |
Recent future growth updates
Recent updates
We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully
Jun 03We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully
Nov 13We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate
Jun 08We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth
Feb 14We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely
Aug 26Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation
May 12We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully
Dec 23Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation
Jun 24We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth
Mar 11Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?
Nov 26Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
6/30/2027 | 4 | N/A | N/A | N/A | 1 |
6/30/2026 | 1 | -20 | -9 | -11 | 2 |
6/30/2025 | 3 | -48 | -4 | -9 | 1 |
6/30/2024 | 3 | -12 | -10 | -10 | N/A |
3/31/2024 | 3 | -11 | -10 | -10 | N/A |
12/31/2023 | 2 | -11 | -10 | -10 | N/A |
9/30/2023 | 2 | -11 | -9 | -9 | N/A |
6/30/2023 | 2 | -11 | -8 | -8 | N/A |
3/31/2023 | 2 | -10 | -7 | -7 | N/A |
12/31/2022 | 2 | -8 | -7 | -7 | N/A |
9/30/2022 | 2 | -7 | -7 | -7 | N/A |
6/30/2022 | 2 | -6 | -8 | -8 | N/A |
3/31/2022 | 1 | -7 | -8 | -8 | N/A |
12/31/2021 | 1 | -9 | -8 | -8 | N/A |
9/30/2021 | 1 | -9 | -7 | -7 | N/A |
6/30/2021 | 1 | -8 | -6 | -6 | N/A |
3/31/2021 | 1 | -6 | -5 | -5 | N/A |
12/31/2020 | 1 | -4 | -4 | -4 | N/A |
9/30/2020 | 1 | -5 | -4 | -4 | N/A |
6/30/2020 | 1 | -6 | -4 | -4 | N/A |
3/31/2020 | 1 | -6 | -3 | -3 | N/A |
12/31/2019 | 1 | -6 | -3 | -3 | N/A |
9/30/2019 | 1 | -4 | -3 | -3 | N/A |
6/30/2019 | 1 | -3 | -3 | -3 | N/A |
3/31/2019 | 0 | -3 | -3 | -3 | N/A |
12/31/2018 | 0 | -3 | -3 | -3 | N/A |
9/30/2018 | 0 | -3 | -3 | -3 | N/A |
6/30/2018 | 0 | -2 | -2 | -2 | N/A |
3/31/2018 | 0 | -2 | N/A | -2 | N/A |
12/31/2017 | 0 | -2 | N/A | -3 | N/A |
9/30/2017 | 1 | -3 | N/A | -3 | N/A |
6/30/2017 | 1 | -3 | N/A | -3 | N/A |
3/31/2017 | 1 | -2 | N/A | -2 | N/A |
12/31/2016 | 1 | -2 | N/A | -2 | N/A |
9/30/2016 | 2 | -2 | N/A | -2 | N/A |
6/30/2016 | 2 | -3 | N/A | -2 | N/A |
3/31/2016 | 3 | -1 | N/A | -1 | N/A |
12/31/2015 | 4 | 1 | N/A | 0 | N/A |
9/30/2015 | 5 | 1 | N/A | 1 | N/A |
6/30/2015 | 5 | 1 | N/A | 1 | N/A |
3/31/2015 | 3 | -1 | N/A | -1 | N/A |
12/31/2014 | 1 | -3 | N/A | -3 | N/A |
9/30/2014 | 1 | -3 | N/A | -3 | N/A |
6/30/2014 | 1 | -3 | N/A | -3 | N/A |
3/31/2014 | 1 | -3 | N/A | -2 | N/A |
12/31/2013 | 1 | -3 | N/A | -2 | N/A |
9/30/2013 | 1 | -3 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PER is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: PER is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: PER is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: PER's revenue is expected to decline over the next 3 years (-0.9% per year).
High Growth Revenue: PER's revenue is forecast to decline over the next 3 years (-0.9% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PER is forecast to be unprofitable in 3 years.